Reference : 1) Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS 3rd, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver WD, Wolff AC, Winer EP, American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703-20. 2) Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106:4-16. 3) Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Maisonneuve P, Gatti G, Mazzarol G, De Cicco C, Manfredi G, FernViaez JR. Sentinel-lymph node biopsy as a staging procedure in breast cancer: update of a randomized controlled study. Lancet Oncol. 2007; 7:983–9. 4) Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Mammolito DM, McCready DR, Mamounas EP, Costantino JP, Wolmark N. National Surgical Adjuvant Breast and Bowel Project, Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881-8. 5) Takei H, Suemasu K, Kurosumi M, Uchida K, Igarashi K, Ninomiya J, Naganuma R, Kusawake T, Sugamata N, Matsumoto H, Higashi Y. Sentinel lymph node biopsy without axillary dissection after an intraoperative negative histological investigation in 358 invasive breast cancer cases. Breast Cancer. 2002;9:344–8. 6) Takei H, Suemasu K, Kurosumi M, HoriiY, Yoshida T, Ninomiya J, Yoshida M, Hagiwara Y, Kamimura M, Hayashi Y, Inoue K, Tabei T, Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer. Breast Cancer 2007; 14:16–24. 7) Takei H, Kurosumi M, Yoshida T, Ninomiya J, Hagiwara Y, Kamimura M, Hayashi Y, Tozuka K, Suemasu K, Inoue K, Tabei T. Current trends of sentinel lymph node biopsy for breast cancer - a surgeon’s perspective. Breast Cancer. 2007;14:362-70. 8) Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial. Semin Surg Oncol 2001;20:230-7. 9) Fant JS, Grant MD, Knox SM, Livingston SA, Ridl K, Jones RC, Kuhn JA. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol. 2003;10:126-30. 10) Fournier K, Schiller A, Perry RR, Laronga C. Micrometastasis in the sentinel lymph node of breast cancer does not mandate complete axillary dissection. Ann Surg. 2004;239:859-63. 11) Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, Port E, Sacchini V, Sclafani L, VanZee K, Wagman R, Borgen PI, Cody HS 3rd. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462-71. 12) Jeruss JS, Winchester DJ, Sener SF, Brinkmann EM, Bilimoria MM, Barrera E Jr, Alwawi E, Nickolov A, Schermerhorn GM, Winchester DJ. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol. 2005;12:34-40. 13) Langer I, Marti WR, Guller U, Moch H, Harder F, Oertli D, Zuber M. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg. 2005;241:152-58. 14) Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, Babiera GV, Tereffe W, Liu DD, Hunt KK. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110:723-30. 15) Zakaria S, Pantvaidya G, Reynolds CA, Grant CS, Sterioff S, Donohue JH, Farley DR, Hoskin TL, Degnim AC. Sentinel node positive breast cancer patients who do not undergo axillary dissection: are they different? Surgery. 2008;143:641-7. 16) Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087-106. 17) Takei H, Kurosumi M, Yoshida T, Ninomiya J, shikawa Y, Hayashi Y, Tozuka K, Asakawa H, Oba H, Inoue K, Tabei T. Positive sentinel lymph node biopsy predicts the number of metastatic axillary nodes of breast cancer. Breast. 2009 (in press). 18) Alkhatib W, Connor C, Fang F. Solitary positive sentinel lymph node accompanied by negative sentinellymph node(s) in predictive of a negative completion axillary lymph node dissection. Am J Surg. 2007;194:856-9. 19) Rivers AK, Griffith KA, Hunt KK, Degninm AC, Sabel MS, Diehl KM, Cimmino VM, Chang AE, Lucas PC, Newman LA. Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann Surg Oncol. 2006; 13:36-44. 20) Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, Borgen PI, Cody HS, Kattan MW. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140–51. 21) Hwang RF, Krishnamurthy S, Hunt KK, Mirza N, Ames FC, Feig B, Kuerer HM, Singletary SE, Babiera G, Meric F, Akins JS, Neely J, Ross MI. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003;10:248–54. 22) Pal A, Provenzano E, Duffy SW, Pinder SE, Purushotham AD. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg. 2008;95:302-9. 23) Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, Rouse RV, Bailey L, Philben VJ, Dirbas FM, Dunn JJ, Johnson DL, Wapnir IL, Carson RW, Stockdale FE, Hansen NM, Jeffery SS, Bay Area SLN Study. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66 24) Park J, Fey JV, Naik AM, Borgen PI, Van Zee KJ, Cody HS 3rd. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg. 2007;245:462-8. 25) Takei H, Suemasu K, Kurosumi M, Horii Y, Ninomiya J, Kamimura M, Naganuma R, Uchida K, Igarashi K, Inoue K, Tabei T. Added value of the presence of blue nodes or hot nodes in sentinel lymph node biopsy of breast cancer. Breast Cancer. 2006;13:179–85. 26) Takei H, Suemasu K, Kurosumi M, Ninomiya J, Horii Y, Inoue K, Tabei T. 99mTc-phytate is better than 99mTc-human serum albumin as a radioactive tracer for sentinel lymph node biopsy in breast cancer. Surg Today. 2006;36:219–24. 27) Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC cancer staging manual. CA Caner J Clin. 2006;56:37-47. 28) Kurosumi M, Suemasu K, Tabei T, Inoue K, Matsumoto H, Sugamata N, Higashi Y, Relationship between existence of lymphatic invasion in peritumoral breast tissue and presence of axillary lymph node metastasis in invasive ductal carcinoma of the breast. Oncol Rep. 2001;8:1051-5. 29) Takei H, Suemasu K, Kurosumi M, Horii Y, Ninomiya J, Yoshida M, Hagiwara Y, Inoue K, Tabei T. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer. Breast J 2006;12 Suppl.2:S157-64. 30) Pugliese MS, Beatty JD, Tickman RJ, Allison KH, Atwood MK, Szymonifka J, Arthurs ZM, Huynh PP, Dawson JH. Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories. Ann Surg Oncol. 2009;16:113-20. 31) Tan LK, Giri D, Hummer AJ, Panageas KS, Brogi E, Norton L, Hudis C, Borgen PI, Cody HS 3rd. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol. 2008;26:1803-9. 32) Cox CE, Kiluk JV, Riker AI, Cox JM, Allred N, Ramos DC, Dupont EL, Vrcel V, Diaz N, Boulware D. Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg. 2008;206:261-8. 33) Spruit PH, Siesling S, Elferink MA, Vonk EJ, Hoekstra CJ. Regional radiotherapy versus an axillary lymph node dissection after lumpectomy: a safe alternative for an axillary lymph node dissection in a clinically uninvolved axilla in breast cancer. A case control study with 10 years follow up. Radiat Oncol. 2007;2:40. 34) Pejavar S, Wilson LD, Haffty BG. Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS+RT). Int J Radiat Oncol Biol Phys. 2006;66:1320-27. 35) Galper S, Recht A, Silver B, Bernardo MV, Gelman R, Wong J, Schnitt SJ, Connolly JL, Harris JR. Is radiation alone adequate treatment to the axilla for patients with limited axillary surgery? Implications for treatment after a positive sentinel node biopsy. Int J Radiat Oncol Biol Phys. 2000;48:125-32. 36) Wong JS, Taghian AG, Bellon JR, Keshaviah A, Smith BL, Winer EP, Silver B, Harris JR. Tangential radiotherapy without axillary surgery in early-stage breast cancer: Results of a prospective trial. Int J Radiat Oncol Biol Phys. 2008;72:866-70. 37) Schlembach PJ, Buchholz TA, Ross MI, Kirsner SM, Salas GJ, Strom EA, McNeese MD, Perkins GH, Hunt KK. Relationship of sentinel and axillary level I-II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys. 2001;51:671-8. 38) European Organization for Research and Treatment of Cancer. Phase III randomized study of complete axillary lymph node dissection versus axillary radiotherapy in sentinel lymph node positive women with operable invasive breast cancer. Available at URL: http://www.clinicaltrials.gov/ct/show/NCT00014612.
less